290 related articles for article (PubMed ID: 12669406)
21. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
22. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
23. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
24. Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation.
Vandenberghe P; Boeckx N; Ronsyn E; Decorte R; Verhoef G; Hagemeijer A
Leukemia; 2003 Feb; 17(2):458-60. PubMed ID: 12592347
[No Abstract] [Full Text] [Related]
25. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
26. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
27. Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation.
Montefusco E; Mauro FR; Lo Coco F; Rondinelli B; Arcese W; Tabilio A; Monarca B; Alimena G; Mandelli F
Haematologica; 1990; 75(4):391-3. PubMed ID: 2276682
[TBL] [Abstract][Full Text] [Related]
28. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
[TBL] [Abstract][Full Text] [Related]
29. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
[TBL] [Abstract][Full Text] [Related]
30. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
31. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
32. Chronic myelogenous leukaemia (CML): an update.
Kumar L
Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
[TBL] [Abstract][Full Text] [Related]
33. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
[TBL] [Abstract][Full Text] [Related]
34. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Moser AM; Manor E; Narkis G; Kapelushnik J
Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
[TBL] [Abstract][Full Text] [Related]
35. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
36. [Therapy of chronic myelogenous leukemia in 2004].
Hochhaus A; Berger U; Hehlmann R
Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
[TBL] [Abstract][Full Text] [Related]
37. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
39. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
[TBL] [Abstract][Full Text] [Related]
40. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
